# THETIS PHARMACEUTICALS, LLC: Development of TP-317 for Ulcerative Colitis

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | THETIS PHARMACEUTICALS, LLC |
| Location | DEEP RIVER, CT |
| Project | Development of TP-317 for Ulcerative Colitis |
| Project number | 1SB1DK145287-01A1 |
| Mechanism | SB1 |
| Institute | National Institute of Diabetes and Digestive and Kidney Diseases |
| Award | $669,925 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-22 to 2028-07-31 |
| UEI | QBDWD3M7YKM9 |

## Why this score
- Award of $400K or more.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11406737). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.